Evidence map›Paper›PMID 42065994›Full record

ArticleACS chemical neuroscience2026

Activity of Nonhallucinogenic Ibogalogs on Chemotherapy-Induced Peripheral Neuropathic Pain in Mice.

Jason Younkin, Eda Koseli, Belle Buzzi, Edward Choi, Torin Honaker, Randall L Davis, Dina Manetti, Maria Novella Romanelli, Aysel Cetinkaya-Fisgin, Hugo R Arias and 3 more

Abstract read
In one paragraph

Article in ACS chemical neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jason YounkinDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia 23298, United States.
Eda KoseliDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia 23298, United States.
Belle BuzziDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia 23298, United States.
Edward ChoiDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia 23298, United States.
Torin HonakerDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia 23298, United States.
Randall L DavisDepartment of Pharmacology and Physiology, Oklahoma State University - Center of Health Sciences, Tulsa and Tahlequah, Oklahoma 74107, United States.
Dina ManettiDepartment of Neurosciences, Psychology, Drug Research and Child Health Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Sesto Fiorentino 50019, Italy.ORCID 0000-0002-5881-6550
Maria Novella RomanelliDepartment of Neurosciences, Psychology, Drug Research and Child Health Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Sesto Fiorentino 50019, Italy.ORCID 0000-0002-5685-3403
Aysel Cetinkaya-FisginDepartment of Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.
Hugo R AriasDepartment of Pharmacology and Physiology, Oklahoma State University - Center of Health Sciences, Tulsa and Tahlequah, Oklahoma 74107, United States.
Ahmet HokeDepartment of Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.
Javier Gonzalez-MaesoDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia 23298, United States.ORCID 0000-0003-3105-3204
M Imad DamajDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia 23298, United States.ORCID 0000-0002-8859-029X

Funding

Structure and function of the 5HT2A/mGluR2 complex in schizophreniaR01MH084894 · NIMH · VIRGINIA COMMONWEALTH UNIVERSITY · PI Javier Gonzalez-Maeso · 2009 to 2026
$6.8M
NIMH NIH HHS R01 MH084894
6 · The paper itself

Abstract

In this study, we examined the effects of ibogaminalog (DM506), a nonhallucinogenic analog of ibogamine, in a mouse model of chemotherapy-induced peripheral neuropathy (CIPN) induced by paclitaxel. We also assessed the effects of tabernanthalog (TBG) and investigated the potential role of serotonin receptor subtype 2A (5-HT

Indexed as

AnalgesicsNeuralgiaAnimalsAntineoplastic AgentsDisease Models, AnimalDose-Response Relationship, DrugGanglia, SpinalHyperalgesiaMaleMiceMicrogliaPaclitaxelPain MeasurementReceptor, Serotonin, 5-HT2AAnalgesicsAntineoplastic AgentsPaclitaxelReceptor, Serotonin, 5-HT2A5-HT2ARchemotherapychronic painibogalogsmiceneuropathy

Identifiers

PMID42065994
PMCPMC13195654

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.